Irinotecan, Capecitabine

DRUG4 trials

Sponsors

Royal Marsden NHS Foundation Trust, National Cancer Center, Korea, Fudan University

Conditions

Colorectal CancerColorectal NeoplasmsDrug Therapy, CombinationMetastatic Breast CancerSecondaryUpper Gastrointestinal Tumours

Phase 2

Study of Irinotecan & Capecitabine in Metastatic Colorectal Cancer

TerminatedNCT00506168

National Cancer Center, KoreaColorectal Neoplasms, Drug Therapy, Combination, Secondary

Start: 2001-11-30End: 2007-07-31Updated: 2007-07-25

Study of Irinotecan Plus Capecitabine to Treat Advanced Colorectal Cancer

CompletedNCT01322152

Fudan UniversityColorectal Cancer

Start: 2011-03-31End: 2013-06-30Updated: 2013-06-11

Phase 3

Irinotecan/Capecitabine Versus Capecitabine in Patients Treated With A/T for HER2 Negative Metastatic Breast Cancer

National Cancer Center, KoreaMetastatic Breast Cancer

Start: 2011-06-30End: 2014-02-28Target: 222Updated: 2012-07-18

Phase 4

Phase II Trial Evaluating Irinotecan and Capecitabine Relapsed/Refractory Upper GI Tumours

CompletedNCT00220168

Royal Marsden NHS Foundation TrustUpper Gastrointestinal Tumours

Start: 2003-01-31Updated: 2009-12-16

Related Papers

Phase II study of weekly irinotecan and capecitabine treatment in metastatic colorectal cancer patients

BMC Cancer2014-12-017 citations

Abstract OT3-1-08: The PROCEED trial KCSG BR11-01: Phase III multicenter randomized open label study of irinotecan plus capecitabine versus capecitabine in patients previously treated with anthracycline and taxane for HER2 negative metastatic breast cancer

Cancer Research2013-12-15